MicroRNAs and their delivery in diabetic fibrosis

Wonnacott, Alexa ORCID: https://orcid.org/0000-0002-0968-4248, Denby, Laura, Coward, Richard J. M., Fraser, Donald J. and Bowen, Timothy ORCID: https://orcid.org/0000-0001-6050-0435 2022. MicroRNAs and their delivery in diabetic fibrosis. Advanced Drug Delivery Reviews 182 , 114045. 10.1016/j.addr.2021.114045

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

The global prevalence of diabetes mellitus was estimated to be 463 million people in 2019 and is predicted to rise to 700 million by 2045. The associated financial and societal costs of this burgeoning epidemic demand an understanding of the pathology of this disease, and its complications, that will inform treatment to enable improved patient outcomes. Nearly two decades after the sequencing of the human genome, the significance of noncoding RNA expression is still being assessed. The family of functional noncoding RNAs known as microRNAs regulates the expression of most genes encoded by the human genome. Altered microRNA expression profiles have been observed both in diabetes and in diabetic complications. These transcripts therefore have significant potential and novelty as targets for therapy, therapeutic agents and biomarkers.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	0169-409X
Date of First Compliant Deposit:	4 July 2022
Date of Acceptance:	4 November 2021
Last Modified:	11 Nov 2024 06:30
URI:	https://orca.cardiff.ac.uk/id/eprint/150543

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item